Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US8740602052
12,80 € ↓ -0,10 (-0,78%)
2026-06-04
AKTIENPREIS
SecurityDE:TKDA / Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)
InstitutionCreative Planning
Latest Disclosed Ownership542,996 shares
Latest Disclosed Value $ 10,056,285
Creative Planning reports 37.33% increase in ownership of TKDA / Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock)

On May 12, 2026 - Creative Planning filed a 13F-HR form disclosing ownership of 542,996 shares of Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock) (DE:TKDA) valued at $8,579,337 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 395,390 shares of Takeda Pharmaceutical Company Limited - Depositary Receipt (Common Stock). This represents a change in shares of 37.33% during the quarter. The current value of the position is $6,950,349 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 542,996 147,606 37.33 10,056 63.14 0.0067
2026-02-17 2025-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 395,390 -68,004 -14.68 6,164 -9.14 0.0044
2025-11-14 2025-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 463,394 91,339 24.55 6,784 17.96 0.0052
2025-08-08 2025-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 372,055 72,494 24.20 5,752 29.12 0.0049
2025-05-15 2025-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 299,561 48,219 19.18 4,454 33.87 0.0042
2025-02-14 2024-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 251,342 93,712 59.45 3,328 48.46 0.0032
2024-10-11 2024-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 157,630 49,871 46.28 2,242 60.76 0.0022
2024-08-15 2024-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 107,759 -37,369 -25.75 1,394 -30.82 0.0015
2024-05-13 2024-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 145,128 39,012 36.76 2,016 33.09 0.0022
2024-02-14 2023-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 106,116 -18,877 -15.10 1,514 -21.68 0.0028
2023-11-16 2023-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 124,993 -1,951 -1.54 1,934 -3.06 0.0026
2023-07-21 2023-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 126,944 27,768 28.00 1,994 22.03 0.0027
2023-05-15 2023-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 99,176 33,116 50.13 1,634 58.64 0.0024
2023-02-10 2022-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 66,060 -1,280 -1.90 1,031 17.98 0.0015
2022-11-03 2022-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 67,340 25,057 59.26 873 46.97 0.0015
2022-08-15 2022-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 42,283 5,779 15.83 594 13.58 0.0010
2022-05-16 2022-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 36,504 5,283 16.92 523 22.77 0.0008
2022-02-11 2021-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 31,221 -4,071 -11.54 426 -26.30 0.0007
2021-11-10 2021-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 35,292 2,893 8.93 578 6.06 0.0010
2021-08-04 2021-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 32,399 -11,366 -25.97 545 -31.79 0.0010
2021-04-30 2021-03-31 13F CreativePlanning SPONSORED ADS 874060205 43,765 8,806 25.19 799 25.63 0.0016
2021-01-29 2020-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 34,959 -18,425 -34.51 636 -33.19 0.0014
2020-11-05 2020-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 53,384 8,347 18.53 952 17.82 0.0025
2020-07-23 2020-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 45,037 -3,687 -7.57 808 9.19 0.0023
2020-05-05 2020-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 48,724 -180 -0.37 740 -23.32 0.0026
2020-01-30 2019-12-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 48,904 -2,919 -5.63 965 8.31 0.0029
2019-11-01 2019-09-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 51,823 314 0.61 891 -2.30 0.0029
2019-07-26 2019-06-30 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 51,509 13,679 36.16 912 18.29 0.0031
2019-04-24 2019-03-31 13F TAKEDA PHARMACEUTICAL SPONSORED ADS 874060205 37,830 37,830 771 0.0028
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.